Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study
Annals of the Rheumatic Diseases · 2026-10 · 85 (10) · 2033-2043
DOI: 10.1016/j.ard.2026.03.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-10. Verfasst von Yohei Kirino und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Electronic address: kirino@yoko…. Hauptthemen laut MEDLINE: Ubiquitin-Activating Enzymes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Government of Japan Ministry of Health Labour and Welfare, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
OBJECTIVES: Vacuole, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome (VS) is a severe autoinflammatory disease caused by acquired pathogenic UBA1 variants and is associated with high mortality. This study aimed to identify predictors of poor outcomes in VEXAS syndrome. METHODS: We conducted a nationwide prospective registry in Japan, in which all suspected cases underwent next-generation sequencing to detect pathogenic UBA1 variants and estimate the variant allele frequency (VAF) at baseline. Disease activity (VEXAS Current Activity Form [VEXASCAF]), serum C-reactive protein (CRP) level, prednisolone (PSL) dose, adverse events (AEs), mortality, and transfusion dependency were evaluated every 3 months for 1 year. RESULTS: Among the screened patients, we included 60 patients with pathogenic UBA1 variants (all males; median age, 74 years) and 45 male patients with VS-like syndrome of similar age but without UBA1 variants served as controls. During a median follow-up of 343 days, the VEXASCAF and CRP levels decreased, whereas the PSL dose did not significantly change. Grade ≥3 AEs occurred in 50% of patients within 1 year. In the multivariable Cox regression analysis, a higher baseline VAF and higher PSL dose independently predicted poor prognosis, defined as death or transfusion dependence. The association between a higher VAF and poor outcomes was confirmed in 34 independent patients with VS. After adjusting for disease onset, patients carrying the UBA1 p.Met41Leu variant showed better survival. A similarly poor prognosis was observed in VEXAS-like patients. CONCLUSIONS: Baseline pathogenic UBA1 VAF serves as a potent prognostic biomarker for poor outcomes in VS and highlights its potential role in risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Electronic address: kirino@yokohama-cu.ac.jp.
- Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Chemotherapy Center, Yokohama City University Hospital, Yokohama, Japan.
- Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.
- Division of Rheumatology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
- Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Förderung
- Government of Japan Ministry of Health Labour and Welfare
- Japan Agency for Medical Research and Development
Zitieren
APA
Kirino, Y., Maeda, A., Higashitani, K., Horita, N., Asano, T., Migita, K., Motomura, Y., Rokutanda, R., Kobayashi, D., Tamura, M., Kanazawa, N., Furuhashi, K., Kondo, Y., Nagahata, K., Takahashi, H., Kobayashi, H., Yao, S., Yamagami, K., Uchino, K., …, & Kishimoto, M. (2026). Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study. Annals of the Rheumatic Diseases, 85(10), 2033-2043. https://doi.org/10.1016/j.ard.2026.03.003
Vancouver
Kirino Y, Maeda A, Higashitani K, Horita N, Asano T, Migita K, et al. Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study. Annals of the Rheumatic Diseases. 2026;85(10):2033-2043. doi:10.1016/j.ard.2026.03.003
BibTeX
@article{Kirino2026,
author = {Kirino, Yohei and Maeda, Ayaka and Higashitani, Kana and Horita, Nobuyuki and Asano, Tomoyuki and Migita, Kiyoshi and Motomura, Yoshikazu and Rokutanda, Ryo and Kobayashi, Daisuke and Tamura, Masao and Kanazawa, Nobuo and Furuhashi, Kazunori and Kondo, Yasushi and Nagahata, Ken and Takahashi, Hiroki and Kobayashi, Hiroshi and Yao, Shuhei and Yamagami, Keiko and Uchino, Kaori and Hidaka, Yukiko and Ida, Hiroaki and Kishida, Dai and Sato, Tomohito and Ichinose, Kunihiro and Miyamae, Takako and Tsujimoto, Kohei and Inoue, Yuta and Fujieda, Yuichiro and Mishima, Koji and Tsuji, Tomohiro and Tanaka, Kazuki and Noda, Haruka and Isogai, Shuntaro and Miyoshi, Yuji and Yokogawa, Naoto and Ota, Shinji and Sakuraba, Hirotake and Nishi, Jumpei and Inoue, Takuya and Muraoka, Sei and Nanki, Toshihiro and Shimizu, Toshimasa and Koga, Tomohiro and Inaba, Yutaka and Matsubara, Masaki and Yoshimoto, Kiyomi and Hasegawa, Anna and Ikeda, Kei and Motohashi, Rena and Takeuchi, Yoichi and Shiratsuchi, Motoaki and Moriyama, Masayori and Noda, Kentaro and Saito, Shinichiro and Hagiyama, Hiroyuki and Honda, Tetsuya and Kageyama, Reiko and Nakatani, Norie and Goto, Tatsunori and Kishimoto, Mitsumasa},
title = {Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {10},
pages = {2033--2043},
doi = {10.1016/j.ard.2026.03.003}
}
EUVIMED